Search Result

Results for "

Cholanoic Acid(Standard)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	G protein-coupled Bile Acid Receptor 1 (4) Antibiotic (1) Apoptosis (1) Autophagy (1) Bacterial (1) Caspase (1) CGRP Receptor (2) COX (1) Endogenous Metabolite (5) Ferroportin (1) Fungal (1) GCGR (5) GLP Receptor (6) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (1) Mitophagy (1) NF-κB (1) Oxytocin Receptor (1) p38 MAPK (1) PD-1/PD-L1 (2) Phospholipase (1) PKC (2) Reactive Oxygen Species (1) ROR (1) Vasopressin Receptor (3) Virus Protease (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (1) Endocrinology (1) Infection (3) Inflammation/Immunology (5) Metabolic Disease (17) Neurological Disease (3)

By Targets:

G protein-coupled Bile Acid Receptor 1 (4)

Antibiotic (1)

Apoptosis (1)

Autophagy (1)

Bacterial (1)

Caspase (1)

CGRP Receptor (2)

COX (1)

Endogenous Metabolite (5)

Ferroportin (1)

Fungal (1)

GCGR (5)

GLP Receptor (6)

Isotope-Labeled Compounds (1)

Mitochondrial Metabolism (1)

Mitophagy (1)

NF-κB (1)

Oxytocin Receptor (1)

p38 MAPK (1)

PD-1/PD-L1 (2)

Phospholipase (1)

PKC (2)

Reactive Oxygen Species (1)

ROR (1)

Vasopressin Receptor (3)

Virus Protease (1)

By Research Areas:

Cancer (7)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (5)

Metabolic Disease (17)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Amino Acid Derivatives Hydroxycarboxylic Acid Receptor (HCAR) Free Fatty Acid Receptor Fatty Acid Synthase (FASN) Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0593

Deoxycholic acid 10+ Cited Publications Cholanoic Acid; Desoxycholic acid	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-14654R

*Aspirin (Standard)* Maximum Cited Publications 16 Publications Verification Acetylsalicylic Acid(Standard); ASA (Standard)	COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Aspirin (Standard) is the analytical standard of Aspirin. This product is intended for research and analytical applications. Aspirin (Acetylsalicylic Acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .

HY-125801

*3-Oxo-5β-cholanoic* acid** Dehydrolithocholic acid; 3-oxoLCA	ROR	Inflammation/Immunology
3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (K_d=1.13 μM) .

HY-18733R

*Lipoic acid (Standard)* 5+ Cited Publications (R)-(+)-α-Lipoic Acid(Standard); R-(+)-Thioctic acid (Standard)	Mitochondrial Metabolism Endogenous Metabolite Reactive Oxygen Species	Inflammation/Immunology Cancer
Lipoic acid (Standard) is the analytical standard of Lipoic acid. This product is intended for research and analytical applications. Lipoic acid ((R)-(+)-α-Lipoic acid) is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. (R)-(+)-α-Lipoic acid is more effective than racemic Lipoic acid.

HY-N0593B

Deoxycholic acid sodium hydrate Cholanoic Acid sodium hydrate; Desoxycholic acid sodium hydrate	Endogenous Metabolite G protein-coupled Bile Acid Receptor 1	Metabolic Disease
Deoxycholic acid (cholanoic acid) sodium hydrate，a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-B0236R

*6-Aminocaproic acid (Standard)* EACA(Standard); Epsilon-Amino-n-caproic Acid(Standard); 6-Aminohexanoic acid (Standard)	Others	Metabolic Disease Cancer
6-Aminocaproic acid (Standard) is the analytical standard of 6-Aminocaproic acid. This product is intended for research and analytical applications. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

HY-N0593S2

Deoxycholic acid-d6 Cholanoic Acid-d₆; Desoxycholic acid-d₆	Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid-d₆ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N0593S3

Deoxycholic acid-13C Cholanoic Acid-¹³C; Desoxycholic acid-¹³C	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid- ¹³C is the ¹³C-labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-P10218A

MANS peptide TFA	PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P10218

MANS peptide	PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P10200

CP7-FP13-2	Bacterial	Infection
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .

HY-P0041

F992

Vasopressin Receptor Neurological Disease

F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .
HY-P0041A

F992 TFA

Vasopressin Receptor Neurological Disease

F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

F992	Vasopressin Receptor	Neurological Disease
F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

F992 TFA	Vasopressin Receptor	Neurological Disease
F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P3462

Cagrilintide	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P3462A

Cagrilintide acetate	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-P5161A

FC382K10W15 TFA

GCGR Metabolic Disease

FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

FC382K10W15 TFA	GCGR	Metabolic Disease
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

HY-P10271

RG7697	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin, which has the ability to continuously improve glycemic control. Meanwhile, ZP3022 can effectively increase the mass of β-cells, promote β-cell proliferation, and enhance the average islet mass. ZP3022 can be used in research for anti-diabetic treatments .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-113560

Plipastatin B1

Antibiotic Fungal Phospholipase Infection

Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A₂ (PLA2), which has antifungal activity .

Plipastatin B1	Antibiotic Fungal Phospholipase	Infection
Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A₂ (PLA2), which has antifungal activity .

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin SKF 100273	Vasopressin Receptor	Metabolic Disease
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P10031A

SAR441255 TFA	GLP Receptor	Metabolic Disease
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P4895

(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin	Oxytocin Receptor	Neurological Disease
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

Cat. No.	Product Name	Target	Research Area